Merck & Co., Inc. Hits New 52-Week High at $124.19

Merck & Co., Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 124.19 on February 23, 2026. This achievement marks a notable recovery for the stock, especially considering its 52-week low of USD 73.31. Despite the recent uptick, Merck's one-year performance reflects a decline of 5.83%, contrasting sharply with the S&P 500's gain of 12.95% during the same period. The company's market capitalization stands at an impressive USD 432,043 million, categorizing it as a large-cap entity. Merck's financial metrics reveal a price-to-earnings (P/E) ratio of 16.00, indicating its valuation relative to earnings. Additionally, the company offers a dividend yield of 3.85%, providing a return to shareholders. With a debt-to-equity ratio of 0.45, Merck maintains a relatively low level of debt, which can be favorable for its financial stability. This recent price movement underscores Merck's position in the market and highlights its ongoing developments within the industry.